Anti-EGFR therapy in oesophagogastric cancer: precise but not enough

Ann Oncol. 2018 Aug 1;29(8):1884-1885. doi: 10.1093/annonc/mdy199.

Authors

M Salati¹, S Cascinu²

Affiliations

¹ Department of Oncology, University Hospital of Modena and Reggio Emilia, Modena, Italy. Electronic address: maxsalati@live.it.
² Department of Oncology, University Hospital of Modena and Reggio Emilia, Modena, Italy.

PMID: 29873680
DOI: 10.1093/annonc/mdy199

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents, Immunological / pharmacology*
Antineoplastic Agents, Immunological / therapeutic use
Clinical Trials as Topic
Drug Resistance, Neoplasm / genetics*
ErbB Receptors / antagonists & inhibitors
ErbB Receptors / genetics
Esophageal Neoplasms / drug therapy*
Esophageal Neoplasms / genetics
Gene Amplification
Humans
Patient Selection*
Precision Medicine
Treatment Failure

Substances

Antineoplastic Agents, Immunological
EGFR protein, human
ErbB Receptors